UPSTREAM BIO, INC. (UPB) Current Ratio
- Current ratio · latest quarter: Value 27.99×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 27.99× | Current assets / current liabilities. $279.60M ÷ $9.99M ≈ 27.99× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 279.60M USD | Assets, Current |
| Current obligations | 9.99M USD | Liabilities, Current |
| Cash and equivalents | 79.40M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 772.00K USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | (m) | |
| Payables | 2.31M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $279.60M | $9.99M | $79.40M | (m) | $772.00K | (m) | $2.31M | (m) | 27.99× |
| 2026-03-31 | $316.28M | $13.67M | $96.72M | (m) | $1.03M | (m) | $1.71M | (m) | 23.14× |
| 2025-12-31 | $351.80M | $13.45M | $101.58M | (m) | $668.00K | (m) | $2.73M | (m) | 26.15× |
| 2025-09-30 | $389.02M | $11.91M | $72.16M | (m) | $683.00K | (m) | $3.95M | (m) | 32.67× |
| 2025-06-30 | $418.27M | $10.93M | $45.46M | (m) | $937.00K | (m) | $2.55M | (m) | 38.27× |
| 2025-03-31 | $453.79M | $9.57M | $71.31M | (m) | $566.00K | (m) | $4.72M | (m) | 47.43× |
| 2024-12-31 | $479.16M | $10.74M | $325.89M | (m) | $613.00K | (m) | $4.04M | (m) | 44.63× |
| 2024-09-30 | $227.27M | $10.87M | $32.95M | (m) | $607.00K | (m) | $4.90M | (m) | 20.90× |
| 2023-12-31 | $117.00M | $6.51M | $25.83M | (m) | $98.00K | (m) | $1.99M | (m) | 17.96× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |